📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Dr. Lal PathLabs Q3 Revenue up 10.6% to Rs 660 Cr; Declares Rs 3.5 Dividend
Dr. Lal PathLabs reported a steady 10.6% YoY revenue growth for Q3 FY26, reaching Rs 660 Cr. While operational EBITDA (before exceptional items) grew strongly by 16.3% with margins expanding to 27.2%, the bottom line was impacted by a one-time exceptional charge of Rs 30.1 Cr related to new labour codes. Consequently, reported PAT declined 6.8% YoY to Rs 91 Cr. The company maintains a robust cash position of Rs 1,411 Cr and declared an interim dividend of Rs 3.5 per share.
Key Highlights
Revenue grew 10.6% YoY to Rs 660 Cr in Q3 FY26, with 9M revenue up 10.8% to Rs 2,060 Cr.
EBITDA before exceptional items rose 16.3% YoY to Rs 179 Cr, with margins improving to 27.2% from 25.8%.
Reported PAT fell 6.8% YoY to Rs 91 Cr due to a Rs 30.1 Cr one-time exceptional impact from new Labour Codes.
Strong liquidity position with cash and bank balances of Rs 1,411 Cr as of December 31, 2025.
Board declared an interim dividend of Rs 3.5 per share for the quarter.
💼 Action for Investors
Investors should focus on the healthy 16.3% growth in operational EBITDA and margin expansion, as the PAT decline is primarily due to a non-recurring exceptional item. The company's strong cash reserves and consistent dividend payout reflect financial stability.
Dr. Lal PathLabs Q3 Revenue Up 10.6% to ₹660 Cr; PAT Impacted by ₹30 Cr Exceptional Item
Dr. Lal PathLabs reported a steady 10.6% YoY revenue growth in Q3 FY26, reaching ₹660 crore, primarily driven by a 7.8% increase in sample volumes. While EBITDA (pre-exceptional) grew strongly by 16.3% to ₹179 crore with margins expanding to 27.2%, the reported PAT declined 6.8% YoY to ₹91 crore. This decline was due to a one-time exceptional charge of ₹30.1 crore related to the impact of new Labour Codes. The company continues to see strong traction in its Swasthfit wellness segment, which now contributes 26% of total revenue.
Key Highlights
Q3 FY26 Revenue grew 10.6% YoY to ₹660 crore, with 9M FY26 revenue crossing ₹2,060 crore.
EBITDA before exceptional items rose 16.3% to ₹179 crore, with margins improving to 27.2% from 25.8% YoY.
Reported PAT fell 6.8% to ₹91 crore following a ₹30.1 crore one-time provision for Labour Codes.
Sample volumes increased by 7.8% to 7.1 million, while patient volumes grew by 3% to 22.2 million in Q3.
Swasthfit wellness program contribution increased to 26% of revenue, up from 23% in the same quarter last year.
💼 Action for Investors
Investors should focus on the robust 16.3% EBITDA growth and margin expansion, as the PAT decline is purely due to a one-time non-operational exceptional item. The steady volume growth and increasing share of high-margin wellness packages (Swasthfit) remain positive long-term indicators.
Dr. Lal Path Labs Q3 Revenue Up 10.6% YoY; Declares INR 3.5 Interim Dividend
Dr. Lal Path Labs reported a 10.6% YoY growth in revenue from operations to INR 6,598 million for Q3 FY26. While operating profit before exceptional items grew to INR 1,544 million, the net profit saw a slight decline to INR 914 million due to a INR 301 million exceptional charge related to labor codes. The company declared its third interim dividend of INR 3.5 per share with a record date of February 5, 2026. Additionally, the board approved the allotment of 4,000 shares under the ESOP scheme.
Key Highlights
Revenue from operations grew 10.6% YoY to INR 6,598 million in Q3 FY26.
Profit before tax and exceptional items stood at INR 1,544 million, up from INR 1,383 million YoY.
Net profit after tax was impacted by a INR 301 million exceptional item related to labor codes, ending at INR 914 million.
Declared a 3rd interim dividend of INR 3.5 per share (35% of face value) with a record date of Feb 5, 2026.
Paid-up equity share capital increased to INR 1,675.55 million following ESOP allotment of 4,000 shares.
💼 Action for Investors
Investors should monitor the impact of the labor code provision on future margins and track volume growth in the core diagnostic business. The dividend provides a steady yield, but the stock's reaction will depend on management's commentary regarding the exceptional cost.
Dr. Lal PathLabs Q3 Results: Revenue Up 10.5%, ₹3.5 Interim Dividend Declared
Dr. Lal PathLabs reported a 10.5% YoY increase in revenue from operations to ₹6,598 million for Q3 FY26. However, net profit attributable to owners declined by 6.4% YoY to ₹905 million, largely due to a ₹301 million exceptional item related to the impact of new labour codes. The Board has declared a third interim dividend of ₹3.5 per share, with the record date set for February 5, 2026. Additionally, the company expanded its equity base slightly by allotting 4,000 shares under its ESOP 2010 plan.
Key Highlights
Revenue from operations grew 10.5% YoY to ₹6,598 million in Q3 FY26.
Net profit for the quarter stood at ₹905 million, down from ₹967 million in the previous year's corresponding quarter.
Declared a 3rd interim dividend of ₹3.5 per equity share (35% of face value) for FY 2025-26.
Reported a one-time exceptional expense of ₹301 million due to the impact of new Labour codes.
Allotted 4,000 equity shares under ESOP 2010, increasing total paid-up equity to 16,75,55,020 shares.
💼 Action for Investors
Investors should focus on the underlying revenue growth while noting that the profit dip was primarily driven by a one-time exceptional charge. The consistent dividend payout reflects a healthy cash position, making it a hold for long-term investors.
Dr. Lal PathLabs Q3 Revenue Up 10.5% to ₹6,598M; Declares ₹3.5 Interim Dividend
Dr. Lal PathLabs reported a 10.5% YoY growth in revenue from operations, reaching INR 6,598 million for the quarter ended December 31, 2025. While operational profit before exceptional items grew by 11.6% YoY to INR 1,544 million, the net profit (PAT) declined by 6.8% to INR 914 million due to a one-time exceptional charge of INR 301 million related to labor codes. The company declared its third interim dividend of INR 3.5 per share for FY 2025-26, with a record date of February 5, 2026. Additionally, the board approved the allotment of 4,000 equity shares under the ESOP 2010 plan.
Key Highlights
Revenue from operations grew 10.5% YoY to INR 6,598 million in Q3 FY26.
Profit before tax and exceptional items increased by 11.6% YoY to INR 1,544 million.
Net Profit (PAT) stood at INR 914 million, impacted by a one-time exceptional labor code cost of INR 301 million.
Declared a 3rd interim dividend of INR 3.5 per share (35% of face value) with a record date of Feb 5, 2026.
Nine-month (9M FY26) revenue reached INR 20,602 million, up from INR 18,588 million in the previous year.
💼 Action for Investors
Investors should focus on the steady 10.5% top-line growth and operational performance, as the PAT decline is primarily due to a non-recurring exceptional item. The consistent dividend payout remains a positive signal for long-term shareholders.
Dr. Lal PathLabs Declares ₹3.5 Interim Dividend; Q3 Revenue Grows 10.6% YoY
Dr. Lal PathLabs has declared its third interim dividend of ₹3.5 per share for FY 2025-26, with the record date set for February 5, 2026. The company reported a 10.6% YoY increase in Q3 revenue to ₹6,598 million, though net profit for the quarter dipped to ₹914 million from ₹981 million in the previous year. This profit decline was primarily due to a one-time exceptional item of ₹301 million related to the impact of new labor codes. For the nine-month period, the company maintains a healthy growth trajectory with PAT rising 12.1% to ₹3,776 million.
Key Highlights
Declared 3rd interim dividend of ₹3.5 per equity share (35% of face value).
Q3 FY26 revenue from operations rose 10.6% YoY to ₹6,598 million.
Net profit for the quarter stood at ₹914 million, impacted by a ₹301 million exceptional charge.
9M FY26 revenue reached ₹20,602 million compared to ₹18,588 million in the previous year.
Record date for dividend eligibility is February 5, 2026, with payment within 30 days.
💼 Action for Investors
Investors should view the profit dip as a one-time accounting adjustment rather than a business slowdown, given the double-digit revenue growth. The consistent dividend payout remains a positive sign for long-term income-seeking shareholders.
Dr. Lal PathLabs Q3 Revenue Grows 10.6% YoY to ₹6,598M; Declares ₹3.5 Interim Dividend
Dr. Lal PathLabs reported a 10.6% YoY increase in consolidated revenue for Q3 FY26, reaching INR 6,598 million. However, net profit for the quarter declined to INR 914 million from INR 981 million in the previous year, largely due to a one-time exceptional expense of INR 301 million related to labor code impacts. The company has declared a third interim dividend of INR 3.5 per share, maintaining its commitment to shareholder returns. While top-line growth remains healthy, margins were sequentially lower compared to the preceding quarter.
Key Highlights
Revenue from operations increased 10.6% YoY to INR 6,598 million in Q3 FY26.
Net profit (PAT) stood at INR 914 million, down from INR 981 million YoY due to a ₹301 million exceptional item.
Declared a 3rd interim dividend of INR 3.5 per equity share with a record date of February 5, 2026.
Total expenses rose to INR 5,298 million, driven by higher employee benefits and collection center fees.
Basic EPS for the quarter was INR 5.42, compared to INR 5.80 in the corresponding quarter of the previous year.
💼 Action for Investors
Investors should focus on the resilient 10% revenue growth while monitoring the impact of rising operational costs on margins. The dividend payout provides a steady yield, but the sequential dip in performance suggests a cautious watch on volume growth in the coming quarters.
Dr. Lal PathLabs Launches SOVAAKA Wellness Centre to Expand into Premium Preventive Care
Dr. Lal PathLabs has launched SOVAAKA, a premium wellness center in Gurugram, marking its entry into the high-growth preventive healthcare segment. The facility integrates advanced diagnostics like 1.5T MRI and genetic testing with AI-driven insights to offer personalized health programs. This strategic move aims to transition the company from disease detection to predictive wellness, targeting higher-margin lifestyle disease management. As of March 2025, the company operates 298 labs and over 6,607 service centers, providing a strong foundation for scaling such premium initiatives.
Key Highlights
Launched SOVAAKA in Gurugram, a next-generation wellness center blending science and AI technology.
Equipped with high-end diagnostic tools including 1.5T MRI, low-dose CT, and DEXA scanning.
Offers specialized, doctor-designed programs like Eterna for women and Vita for men.
Strategic focus on the growing preventive health market to address rising Non-Communicable Diseases.
Company network includes 298 clinical labs and 12,365 pick-up points as of March 31, 2025.
💼 Action for Investors
This expansion into premium wellness is a positive move to increase average revenue per patient; investors should watch for further rollouts of this format in other metros.
Dr. Lal Path Labs Allots 8.37 Crore Bonus Shares in 1:1 Ratio
Dr. Lal Path Labs has completed the allotment of 8,37,75,510 bonus equity shares to eligible shareholders following its 1:1 bonus issue. The allotment was approved via a circular resolution on December 22, 2025, for shareholders on record as of December 19, 2025. This move doubles the company's total number of outstanding shares to 16,75,51,020. The paid-up equity share capital now stands increased at INR 167.55 crore, with the new shares ranking pari-passu with existing ones.
Key Highlights
Allotment of 8,37,75,510 fully paid-up bonus equity shares of face value INR 10 each.
Bonus issue executed in a 1:1 ratio for shareholders as of the December 19, 2025 record date.
Total paid-up equity capital increased from INR 83.77 crore to INR 167.55 crore.
Total number of equity shares outstanding increased to 16,75,51,020 shares.
New bonus shares rank pari-passu in all respects with existing equity shares.
💼 Action for Investors
Investors should note that while the number of shares in their portfolio has doubled, the stock price has been adjusted proportionally. No further action is required as the allotment is automatic for eligible shareholders.
Dr. Lal PathLabs Increases Authorized Share Capital to INR 200 Crore
Dr. Lal PathLabs has received shareholder approval via postal ballot to significantly increase its authorized share capital. The limit has been raised from INR 107.96 crore to INR 200 crore, effectively doubling the company's capacity to issue new equity. This change involves a formal amendment to Clause V of the Memorandum of Association. While this is a regulatory enabling provision, it often serves as a precursor to future corporate actions such as bonus issues, rights issues, or equity-based fundraising.
Key Highlights
Authorized share capital increased from INR 107.96 crore to INR 200 crore.
Shareholder approval was obtained through a postal ballot concluded on December 07, 2025.
The new capital structure consists of 20,00,00,000 equity shares with a face value of INR 10 each.
Amendment to Clause V of the Memorandum of Association (MOA) has been officially implemented.
💼 Action for Investors
Investors should monitor the company for upcoming announcements regarding bonus issues or capital raises, as this move creates the necessary legal headroom for such actions.
Dr. Lal PathLabs Shareholders Approve Bonus Issue and New 2025 Employee Stock Unit Plan
Dr. Lal PathLabs has announced the successful passage of seven resolutions via postal ballot, most notably the issuance of bonus equity shares and an increase in authorized share capital. The 'Employee Restricted Stock Unit Plan 2025' was approved with 79.81% favor, although it faced significant institutional dissent with 51.5% of institutional votes cast against it. Additionally, shareholders cleared the path for secondary share acquisitions through a trust and a reduction in the 2022 options reserve. These approvals facilitate the company's capital restructuring and long-term incentive programs.
Key Highlights
Bonus Equity Shares issuance approved with 98.04% of total votes in favor.
Increase in Authorized Share Capital passed with a near-unanimous 99.84% majority.
New 'Employee Restricted Stock Unit Plan 2025' secured 79.81% support despite 51.5% institutional pushback.
Secondary acquisition of shares through a Trust route for ESOP implementation approved by 83.76% of voters.
Reduction of Options Reserve under the 2022 ESOP plan approved with 86.80% majority.
💼 Action for Investors
Investors should view the bonus issue as a positive move for share liquidity, though the high institutional dissent on the new ESOP plan suggests a need to monitor future management compensation and dilution.